Dymon Asia Capital Singapore PTE. LTD. Invests $860,000 in Cogent Biosciences, Inc. $COGT

Dymon Asia Capital Singapore PTE. LTD. purchased a new stake in shares of Cogent Biosciences, Inc. (NASDAQ:COGT) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 24,200 shares of the technology company’s stock, valued at approximately $860,000.

A number of other institutional investors also recently modified their holdings of COGT. AQR Capital Management LLC grew its stake in Cogent Biosciences by 482.6% in the 1st quarter. AQR Capital Management LLC now owns 160,767 shares of the technology company’s stock valued at $963,000 after buying an additional 133,174 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Cogent Biosciences by 6.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 62,275 shares of the technology company’s stock worth $377,000 after acquiring an additional 3,693 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Cogent Biosciences by 14.3% in the first quarter. Goldman Sachs Group Inc. now owns 988,962 shares of the technology company’s stock worth $5,924,000 after acquiring an additional 124,069 shares during the period. Jane Street Group LLC boosted its holdings in shares of Cogent Biosciences by 66.2% in the first quarter. Jane Street Group LLC now owns 123,822 shares of the technology company’s stock worth $742,000 after acquiring an additional 49,338 shares during the period. Finally, Strs Ohio bought a new position in shares of Cogent Biosciences in the first quarter worth $36,000.

Cogent Biosciences Trading Up 1.5%

Shares of COGT stock opened at $33.10 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 15.14 and a current ratio of 15.14. Cogent Biosciences, Inc. has a 52-week low of $6.88 and a 52-week high of $43.73. The company has a market capitalization of $5.66 billion, a PE ratio of -15.25 and a beta of 0.34. The business’s fifty day moving average is $34.62 and its 200 day moving average is $36.58.

Cogent Biosciences (NASDAQ:COGT) last issued its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.53). On average, equities research analysts anticipate that Cogent Biosciences, Inc. will post -2.26 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on COGT shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Friday, April 10th. Piper Sandler raised their price target on Cogent Biosciences from $39.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Wedbush reaffirmed an “outperform” rating and issued a $55.00 price target on shares of Cogent Biosciences in a report on Friday, May 29th. HC Wainwright raised their price target on Cogent Biosciences to $55.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Finally, Robert W. Baird set a $35.00 price target on Cogent Biosciences in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Cogent Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $43.73.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.